ClinicalTrials.gg
Not yet recruitingNCT05921227Updated Jul 30, 2025

Addressing Treatment Nonresponders

A Phase 2 interventional study of VAULT Phase 6 in Language Development Disorders, sponsored by University of Arizona. Not yet recruiting. Open to participants aged 2 Years to 4 Years. Per ClinicalTrials.gov, last updated 2025-07-30.

Sponsored by University of Arizona · Phase 2, Interventional, and Treatment

Phase
Phase 2
Study type
Interventional
Enrollment
16
Allocation
Non-randomized
Ages
2 Years to 4 Years
Sex
All
01

Study summary

The goal of this clinical trial is to see if providing late talking toddlers who are not responding to the Vocabulary Acquisition and Usage for Late Talkers (VAULT) treatment with a different way of communicating will help them improve their word learning. Participants will start with VAULT word learning treatment. If, in the first few sessions, it looks like they won't respond well, they will be provided with a Big Mack Augmentative and Alternative Communication device (a button that says a word when you press it) to use for their responses. The investigators will see if this modification will help with word learning.

Read the detailed description

Children will begin Vocabulary Acquisition and Usage for Late Talkers (VAULT) word learning treatment. If, after three sessions, they do not show an initial response to treatment, they will be provided with a Big Mack Augmentative and Alternative Communication device which will allow them to 'say' the treatment words with the device. Treatment will continue until the children have had 8 total weeks of treatment (2x/wk for 30 minutes per session). The investigators will measure word learning across time tracking both spoken productions and productions made with the device.

02

Conditions studied

  • Language Development Disorders

Keywords

  • Late Talkers
03

In context

Language Development Disorders

121 studies on the registry are indexed under Language Development Disorders; 49 are open to participants now.

This study's planned enrollment of 16 is below the median of 74 across 106 interventional studies indexed under Language Development Disorders.

Browse Language Development Disorders studies →

Lead sponsor

University of Arizona is the lead sponsor of 476 studies on the registry; 88 are open to participants now.

Of its 51 completed or terminated interventional studies of FDA-regulated products, 30 (59%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
2 Years to 4 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Native English Speaking
  • Pass pure tone hearing screening or medical report of normal hearing
  • 2-3 years at start of study
  • MacArthur-Bates Communicative Development Inventories (MCDI) expressive scale \<10th percentile

Exclusion criteria

Exclusion Criteria:

  • Parental report of other diagnoses
  • Enrolled in concurrent treatment elsewhere
  • Nonverbal IQ \<75 as measured by the Bayley Scales
  • Parents unable to consistently bring child to treatment sessions.
05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
Double (Participant, Care provider)
Enrollment
16 participants (estimated)

Study arms

  • Experimental
    Alternative Treatment Including Augmentative and Alternative Communication

    Once children are shown to not respond to the usual Vocabulary Acquisition and Usage for Late Talkers (VAULT) treatment, they will be placed in this arm, which will train them to use an Augmentative and Alternative Communication device as an additional means to use to 'say' a word.

    Behavioral: VAULT Phase 6

  • Active comparator
    Usual Vocabulary Acquisition and Usage for Late Talkers (VAULT) treatment

    Children who do appear to respond to treatment will continue with the full course of usual Vocabulary Acquisition and Usage for Late Talkers (VAULT) intervention.

    Behavioral: VAULT Phase 6

Interventions

  • BehavioralVAULT Phase 6

    VAULT is an input-based word learning intervention based on principles of statistical learning.

06

What researchers measure

Primary outcomes

  1. Treatment Effect Size

    The investigators will count the number of spontaneous and probed productions of target and control words and calculate a treatment effect size (d).

    Time frame: Change from baseline through treatment, which will average an 8-week time frame.

  2. Number/Rate of words learned

    The investigators will measure the number of words learned and rate of words learned as reported by the parent on the MCDI starting prior to treatment and measured during, immediately following, and 4-6 weeks after the treatment.

    Time frame: Change from Initial Evaluation through Follow-up, which will average a 6-month time frame.

Secondary outcomes

  1. Post Treatment Retention

    We will use probe data or specific words and parental report to determine how many of the words the child retained from treatment.

    Time frame: Change from end of treatment to follow up, which will average 4-6 weeks.

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Jun 2026; primary completion for Jun 2027, 12 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 14, 2023
First posted
Jun 27, 2023
StartEst.
Jun 2026
Primary completionEst.
Jun 2027
CompletionEst.
Aug 2027
Last update
Jul 30, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 30, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05921227
Responsible party
Sponsor
First posted
Jun 27, 2023
Start date
Jun 2026 (estimated)
Primary completion
Jun 2027 (estimated)
Completion
Aug 2027 (estimated)
Last update
Jul 30, 2025

Study contacts

Mary Alt, PhD
Contact
malt@arizona.edu
520-626-6180
Nora Evans-Reitz, m
Contact
nevansreitz@arizona.edu
520-626-6885
Mary Alt, PhD
principal investigator · University of Arizona

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Jul 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion